Published in BMC Cancer on May 28, 2009
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect (2010) 1.48
Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics (2014) 0.87
Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer. Oncol Rep (2014) 0.86
Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics (2012) 0.82
-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid. Int J Biol Markers (2011) 0.80
Identification of a mimotope for circulating anti-cytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer. Int J Oncol (2012) 0.80
Macrophage migration inhibitory factor involvement in breast cancer (Review). Int J Oncol (2015) 0.78
Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model. PLoS One (2016) 0.75
Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study. BMC Cancer (2015) 0.75
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
Circulating adhesion molecules in disease. Immunol Today (1993) 6.22
Receiver operating characteristic curves and their use in radiology. Radiology (2003) 4.57
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med (1996) 3.82
Bayesian model averaging: development of an improved multi-class, gene selection and classification tool for microarray data. Bioinformatics (2005) 3.21
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science (2002) 3.13
Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood (1989) 3.10
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.90
Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions. Bioinformatics (2003) 2.64
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Feature selection and classifier performance in computer-aided diagnosis: the effect of finite sample size. Med Phys (2000) 1.98
Serum tumor markers in breast cancer: are they of clinical value? Clin Chem (2006) 1.95
The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol (2008) 1.86
Comparing three-class diagnostic tests by three-way ROC analysis. Med Decis Making (2000) 1.80
New prognostic factors for breast cancer recurrence. Semin Oncol (2001) 1.77
Proteomics of human breast ductal carcinoma in situ. Cancer Res (2002) 1.62
Interferon-alpha and autoimmune thyroid disease. Thyroid (2003) 1.53
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem (2002) 1.44
MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J (1996) 1.44
Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. J Neurochem (2003) 1.44
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev (2000) 1.39
Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36
Three-class ROC analysis--a decision theoretic approach under the ideal observer framework. IEEE Trans Med Imaging (2006) 1.31
Macrophage migration inhibitory factor. Expert Opin Ther Targets (2003) 1.28
Changes in the tumor marker concentration in female patients with hyper-, eu-, and hypothyroidism. Endocrinol Jpn (1989) 1.25
Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock. Infect Immun (1997) 1.25
New approaches to proteomic analysis of breast cancer. Proteomics (2001) 1.23
Adrenal cholesterol uptake from plasma lipoproteins: regulation by corticotropin. Proc Natl Acad Sci U S A (1976) 1.21
New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J (2005) 1.14
A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A (2006) 1.13
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol (2007) 1.10
Occult breast abnormalities: percutaneous preoperative needle localization. Radiology (1984) 1.06
Type I interferon gene expression: differential expression of IFN-A genes induced by viruses and double-stranded RNA. Biochimie (1999) 1.04
Estimating three-class ideal observer decision variables for computerized detection and classification of mammographic mass lesions. Med Phys (2004) 1.01
Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res (2009) 1.00
High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem (2004) 1.00
Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab (1995) 0.99
Screening mammography for breast cancer: American College of Preventive Medicine practice policy statement. Am J Prev Med (1997) 0.99
Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev (2007) 0.98
Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat (1989) 0.98
Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat (2006) 0.98
Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics (2003) 0.98
Methodology and applications of disease biomarker identification in human serum. Biomark Insights (2007) 0.97
Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J Proteome Res (2008) 0.96
Clinically occult breast lesions: localization and significance. Radiology (1987) 0.95
Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: a case-control study. J Proteome Res (2008) 0.92
Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology (2004) 0.91
Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/beta-thalassaemia. Br J Haematol (2006) 0.90
Tumor marker kinetics in the monitoring of breast cancer. Cancer (1990) 0.89
Proteomic approach to breast cancer. Cancer Control (2007) 0.88
Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res (2004) 0.87
Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics (2007) 0.87
Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women. Pathol Oncol Res (2007) 0.84
Needle localization biopsy of occult lesions of the breast. Experience in 199 cases. Invest Radiol (1988) 0.83
CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol (2005) 0.83
Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena. Clin Biochem (1997) 0.83
SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. Cancer Biomark (2006) 0.81
CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark (2008) 0.81
Type I collagen induces tissue factor expression and matrix metalloproteinase 9 production in human primary monocytes through a redox-sensitive pathway. J Thromb Haemost (2008) 0.81
[Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer]. Hell J Nucl Med (2006) 0.76
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.90
MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med (2008) 2.79
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
General conditions for predictivity in learning theory. Nature (2004) 2.16
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90
Gene expression changes and molecular pathways mediating activity-dependent plasticity in visual cortex. Nat Neurosci (2006) 1.86
Breast tomosynthesis: state-of-the-art and review of the literature. Acad Radiol (2011) 1.83
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76
Evidence-ranked motif identification. Genome Biol (2010) 1.75
Comparative study of gene set enrichment methods. BMC Bioinformatics (2009) 1.74
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res (2006) 1.74
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Evaluation of information-theoretic similarity measures for content-based retrieval and detection of masses in mammograms. Med Phys (2007) 1.71
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (2005) 1.71
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol (2012) 1.63
Reproducibility of serum cytokines and growth factors. Cytokine (2008) 1.61
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
Evidence of influence of genomic DNA sequence on human X chromosome inactivation. PLoS Comput Biol (2006) 1.52
Computer-aided classification of breast masses: performance and interobserver variability of expert radiologists versus residents. Radiology (2010) 1.50
Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles. Bioinformatics (2006) 1.49
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res (2006) 1.43
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One (2009) 1.40
Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev (2007) 1.38
Importance of point-by-point back projection correction for isocentric motion in digital breast tomosynthesis: relevance to morphology of structures such as microcalcifications. Med Phys (2007) 1.34
Optimal gene expression analysis by microarrays. Cancer Cell (2002) 1.34
Analgesic drug use and risk of ovarian cancer. Epidemiology (2006) 1.33
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One (2010) 1.28
The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One (2009) 1.28
Prediction and uncertainty in the analysis of gene expression profiles. In Silico Biol (2002) 1.27
Optimized image acquisition for breast tomosynthesis in projection and reconstruction space. Med Phys (2009) 1.24
Optimization of exposure parameters in full field digital mammography. Med Phys (2008) 1.24
Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep (2013) 1.24
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol (2005) 1.23
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets. Genome Res (2011) 1.20
ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther (2008) 1.19
Optimized approach to decision fusion of heterogeneous data for breast cancer diagnosis. Med Phys (2006) 1.18
Training neural network classifiers for medical decision making: the effects of imbalanced datasets on classification performance. Neural Netw (2007) 1.18
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res (2011) 1.17
Fundamental imaging characteristics of a slot-scan digital chest radiographic system. Med Phys (2004) 1.16
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16
Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryot Cell (2004) 1.16
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res (2006) 1.16
Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur Cytokine Netw (2009) 1.16
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 1.15
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol (2009) 1.15
A mathematical model platform for optimizing a multiprojection breast imaging system. Med Phys (2008) 1.15
Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control (2010) 1.14
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer (2012) 1.14
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.14
Biological significance of prolactin in gynecologic cancers. Cancer Res (2009) 1.13
A framework for optimising the radiographic technique in digital X-ray imaging. Radiat Prot Dosimetry (2005) 1.10
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res (2008) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. J Am Coll Surg (2010) 1.09
Genetics of gene expression responses to temperature stress in a sea urchin gene network. Mol Ecol (2012) 1.08
Breast mass lesions: computer-aided diagnosis models with mammographic and sonographic descriptors. Radiology (2007) 1.08
Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer (2004) 1.08
Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine (2007) 1.07
Gene expression programs of human smooth muscle cells: tissue-specific differentiation and prognostic significance in breast cancers. PLoS Genet (2007) 1.07
Cyclin-dependent kinases are regulators and effectors of oscillations driven by a transcription factor network. Mol Cell (2012) 1.07
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene (2005) 1.06
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol (2011) 1.06
Information-theoretic CAD system in mammography: entropy-based indexing for computational efficiency and robust performance. Med Phys (2007) 1.05
Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol (2012) 1.05
Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res (2004) 1.05
A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res (2014) 1.04
Automated breast mass detection in 3D reconstructed tomosynthesis volumes: a featureless approach. Med Phys (2008) 1.04
IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev (2005) 1.04
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res (2009) 1.03